Clinical trials: Colon Cancer Stage I
Colon Cancer, Colorectal Cancer
Study of Xeloda and Gleevec in Patients With Advanced Solid Tumors
This study is for people with solid tumors cancer for which the standard chemotherapy drugs have not worked. The purpose of this research is to evaluate the side effects of Xeloda (also called capecitabine) in combination with a…
- Trial name
- NCT00183833
- Testing
- capecitabine, imatinib mesylate
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Southern California
Colon Lesions
A Phase I In-Vivo Peptide Applied in the Right Colon
You are invited to participate in a research study to develop new ways to look for abnormal areas/tissues of the colon. The current endoscopes used to look at the colon are very good, but if the area doesn't look different to the…
- Trial name
- NCT01722058
- Testing
- Peptide application
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- University of Michigan
Colorectal Cancer
Evaluation of the Efficacy and the Safety of FOLFIRINOX3 Bevacizumab Treatment in Patients With Colorectal Cancer (FOLFIRINOX 3)
In patients in progression after oxaliplatin and irinotecan, the study FOLFIRINOX 3 proposes to evaluate the interest of modifying the standard pattern of administration of the molecule of irinotecan in order to make it more…
- Trial name
- FOLFIRINOX3 (NCT03795311)
- Testing
- FOLFIRINOX Bevacizumab
- Where
- France
- Volunteers
- 32 people
- Sponsor
- Centre Georges Francois Leclerc
Colorectal Cancer
Robotic Versus Laparoscopy NOSE for Stage I-III Left-sided Colon Cancer
In this project, the investigator aims to provide the level 1 evidence for the comparison of robotic versus laparoscopic NOSE for the surgery of stage I-III colorectal cancer.
- Trial name
- NCT05970133
- Testing
- Colectomy with NOSE procedure
- Where
- Taiwan
- Volunteers
- 300 people
- Sponsor
- National Taiwan University Hospital
Colorectal Cancer, Quality of Life
RESPONSE: Colorectal Cancer Survivors' Follow-up Care - Now Digital and Need-based
Over the last decades, the 3-year recurrence rates for patients with stage I and II colorectal cancer have decreased to just 5% and 12%.
- Conditions
- Colorectal Cancer, Quality of Life, Survivorship
- Trial name
- RESPONSE (NCT06614647)
- Testing
- Recurrence monitoring with circulating tumor DNA (ctDNA) as a high risk biomarker, Monitoring for late adverse effects with electronic patient reported outcome measures (ePROMs), Systematic treatment of organ-specific late effects and/or biopsychosocial late effects
- Where
- 9 sites in Denmark
- Volunteers
- 400 people
- Sponsor
- University of Aarhus
Locally Advanced or Metastatic Epithelial Tumor
A Study of SI-B001, an EGFR/HER3 Bispecific Antibody, in Locally Advanced or Metastatic Epithelial Tumors
In phase Ia study, the safety and tolerability of SI-B001 in patients with locally advanced or metastatic epithelial malignancies will be investigated to determine the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) of…
- Trial name
- NCT04603287
- Testing
- SI-B001
- Where
- 3 sites in China
- Volunteers
- 60 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Colorectal Cancer
Peptide Vaccine and S-1/CPT-11 Therapy for Patients With Unresectable Advanced Colorectal Cancer
The purpose of this study is to evaluate the safety and immune response of different doses of RNF43-721 emulsified with Montanide ISA 51 in combination with S-1/CPT-11 chemotherapy.
- Trial name
- NCT00641615
- Testing
- RNF43-721
- Where
- Japan
- Volunteers
- 18 people
- Sponsor
- Kazuhiko Yoshimatsu
Colorectal Cancer
Phase I / II Study of Irinotecan (CPT-11) Combined With l-Leucovorin (l-LV) and 5-FU in Patients With Advanced Colorectal Cancer
We performed a phase I/II study of CPT-11/5FU/l-LV in advanced colorectal cancer, to determine the optimal dose of CPT-11 and to estimate the safety and efficacy of this regimen
- Trial name
- NCT00209625
- Testing
- irinotecan, leucovorin, fluorouracil
- Where
- Japan
- Volunteers
- 23 people
- Sponsor
- Hokkaido Gastrointestinal Cancer Study Group
Colorectal Cancer, Lung Cancer
A Study of DCTY1102 Injection in Participants With Advanced Solid Tumors
This is a Phase 1/2, open-label, single-arm, multicenter study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of DCTY1102 Injection in participants with advanced malignant tumors harboring…
- Conditions
- Colorectal Cancer, Lung Cancer, Pancreatic Cancer
- Trial name
- NCT07014878
- Testing
- TCR-T cells
- Where
- 2 sites in China
- Volunteers
- 18 people
- Sponsor
- Beijing DCTY Biotech Co.,Ltd.
Advanced Solid Tumor
A Phase I Study to Evaluate the Safety, Pharmacokinetics and Antitumor Activity of HC010 in Patients With Advanced Solid Tumors
This clinical trial is a multicenter, open, single-arm, non-randomized, dose-escalation and dose-expansion, phase I clinical study in patients with advanced recurrent or metastatic solid tumors.The goal of this study is to…
- Trial name
- NCT06307925
- Testing
- HC010
- Where
- China
- Volunteers
- 122 people
- Sponsor
- HC Biopharma Inc.
Renal Carcinoma Metastatic, Pancreatic Adenocarcinoma Metastatic
A Phase I Study to Evaluate the Safety and Efficacy of L19IL2 in Combination With Ruxolitinib in Patients With Advanced Solid Tumors
This trial aims to address unmet medical needs in advanced solid tumors, specifically metastatic clear cell renal carcinoma, locally advanced or metastatic pancreatic adenocarcinoma, and metastatic colorectal adenocarcinoma.
- Conditions
- Renal Carcinoma Metastatic, Pancreatic Adenocarcinoma Metastatic, Pancreatic Adenocarcinoma, Metastatic Colorectal Carcinoma (mCRC)
- Trial name
- NCT07566897
- Testing
- L19IL2, Ruxolitinib
- Where
- Italy
- Volunteers
- 96 people
- Sponsor
- Philogen S.p.A.
Colorectal Cancer, Colorectal Carcinoma
A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer
Background: Immune-based approaches in colorectal cancer have unfortunately with the notable exception of immune checkpoint inhibition in microsatellite instable (MSI-hi) disease been largely unsuccessful.
- Conditions
- Colorectal Cancer, Colorectal Carcinoma, Colorectal Adenocarcinoma, Refractory Cancer
- Trial name
- NCT03206073
- Testing
- Durvalumab, Tremelimumab, Pexa-Vec
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- National Cancer Institute (NCI)
Regorafenib, Raltitrexed
Regorafenib Plus Raltitrexed as Third-line Treatment in Advanced Colorectal Cancer Patients
This is a multicenter, open, single-arm, phase I/II study to evaluate the efficacy and safety of regorafenib plus raltitrexed as third-line treatment in patients with advanced colorectal cancer.
- Conditions
- Regorafenib, Raltitrexed, Colorectal Neoplasms, Third-line Treatment
- Trial name
- NCT05426811
- Testing
- Regorafenib, Raltitrexed
- Volunteers
- 50 people
- Sponsor
- China Medical University, China
Solid Tumors for Phase Ib, Pancreatic Cancer for Phase II
Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors
Phase Ib dose escalation in advanced solid tumors to identify dose for Phase II dose expansion in advanced or metastatic pancreatic cancer and KRAS-mutant colorectal cancer. Open-label, nonrandomized.
- Conditions
- Solid Tumors for Phase Ib, Pancreatic Cancer for Phase II, Colorectal Cancer for Phase II
- Trial name
- NCT02703571
- Testing
- ribociclib, Trametinib
- Where
- 15 sites in United States, Australia and 5 more
- Volunteers
- 95 people
- Sponsor
- Novartis Pharmaceuticals
Metastatic Colorectal Cancer (MCRC)
Phase I/II Combination With Irinotecan- Erbitux
Part 1: To define the recommended dose of brivanib that can be safely administered in combination with Erbitux (Cetuximab) and irinotecan to subjects with advanced metastatic colorectal cancer (MCRC) Part 2: To compare median…
- Trial name
- NCT00594984
- Testing
- Cetuximab, Irinotecan, Brivanib
- Where
- 12 sites in United States, Argentina and 5 more
- Volunteers
- 38 people
- Sponsor
- Bristol-Myers Squibb
Recurrent Colon Cancer, Recurrent Rectal Cancer
Suberoylanilide Hydroxamic Acid, Fluorouracil, Leucovorin, and Oxaliplatin in Treating Patients With Progressive Metastatic or Unresectable Colorectal Cancer or Other Solid Tumors
This phase I trial is studying the side effects and best dose of suberoylanilide hydroxamic acid when given together with fluorouracil, leucovorin, and oxaliplatin in treating patients with progressive metastatic or unresectable…
- Conditions
- Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage III Colon Cancer, Stage III Rectal Cancer
- Trial name
- NCT00138177
- Testing
- oxaliplatin, leucovorin calcium, vorinostat
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, Colorectal Cancer
Paclitaxel and Bortezomib in Treating Patients With Metastatic or Unresectable Malignant Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Lung Cancer
- Trial name
- NCT00667641
- Testing
- bortezomib, paclitaxel
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of Medicine and Dentistry of New Jersey
Colon Cancer Stage I, Colon Cancer Stage II
Five-year Recurrence After LCME
A register-based study is conducted to examine clinical outcomes following a population-based, multi-centred implementation of Laparoscopic Complete Mesocolic Excision (LCME) in the Central Denmark Region, Denmark.
- Conditions
- Colon Cancer Stage I, Colon Cancer Stage II, Colon Cancer Stage III
- Trial name
- NCT06924931
- Testing
- LCME training programme
- Volunteers
- 2,529 people
- Sponsor
- Gødstrup Hospital
Metastatic Cancer, Colorectal Cancer
A Phase I/II Study of XELOXIRI and Bevacizumab as First-line Treatment in Metastatic Colorectal Cancer
The phase I/II study was designed to evaluate if the regimen of Irinotecan, Oxaliplatin, Capecitabine (XELOXIRI) and Bevacizumab is a superior first-line option for patients with metastatic colorectal cancer(mCRC) in terms of…
- Conditions
- Metastatic Cancer, Colorectal Cancer, Colorectal Adenocarcinoma
- Trial name
- NCT04380103
- Testing
- XELOXIRI/Bevacizumab
- Where
- 2 sites in China
- Volunteers
- 106 people
- Sponsor
- Chinese Academy of Medical Sciences
Breast Cancer, Colorectal Cancer
A Study of CDX-1307, in Patients With Incurable Breast, Colorectal, Pancreatic, Ovarian or Bladder Cancer (CDX 1307-01)
This research study is for individuals who have advanced breast, colon, pancreatic, ovarian or bladder cancer. Celldex Therapeutics, Inc.
- Conditions
- Breast Cancer, Colorectal Cancer, Pancreatic Cancer, Bladder Cancer
- Trial name
- NCT00709462
- Testing
- CDX1307
- Where
- 3 sites in United States
- Volunteers
- 48 people
- Sponsor
- Celldex Therapeutics